Cote, G. M., Chawla, S. P., Demetri, G., Kasper, B., Jones, R. L., Broto, J. M., . . . Le Cesne, A. (2025). SaLudo: A randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future oncology, 21(8), . https://doi.org/10.1080/14796694.2025.2463798
Chicago-Zitierstil (17. Ausg.)Cote, Gregory M., et al. "SaLudo: A Randomized Phase IIb/III Study of Lurbinectedin Plus Doxorubicin as First-line Treatment in Leiomyosarcoma." Future Oncology 21, no. 8 (2025). https://doi.org/10.1080/14796694.2025.2463798.
MLA-Zitierstil (9. Ausg.)Cote, Gregory M., et al. "SaLudo: A Randomized Phase IIb/III Study of Lurbinectedin Plus Doxorubicin as First-line Treatment in Leiomyosarcoma." Future Oncology, vol. 21, no. 8, 2025, https://doi.org/10.1080/14796694.2025.2463798.